Drug Profile
Camptothecin - BlueLink Pharmaceuticals/Calando Pharmaceuticals
Alternative Names: Camptothecin-nanoparticle-cerulean; CRLX 101; Cyclosert-CPT; Cyclosert™-enhanced camptothecin; IT-101; NLG 207Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Insert Therapeutics
- Developer BlueLink Pharmaceuticals; Cerulean Pharma; Insert Therapeutics; Massachusetts General Hospital; National Cancer Institute (USA); University of North Carolina
- Class Antineoplastics; Camptothecins; Drug conjugates; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor-1 alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Ovarian cancer; Prostate cancer; Rectal cancer; Renal cell carcinoma; Small cell lung cancer
- Phase I/II Solid tumours
- No development reported Breast cancer; Gastric cancer; Non-small cell lung cancer
Most Recent Events
- 01 Apr 2021 Camptothecin is still in phase-II clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Late-stage disease, Hormone refractory, Second-line therapy or greater) in USA (IV) (NCT03531827)
- 17 Dec 2019 Camptothecin licensed to Ellipses Pharma worldwide
- 02 Apr 2019 Updated efficacy and adverse events data from a phase Ib/II trial in Ovarian cancer, Fallopian tube or Peritoneal cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2019)